October 1, 2022
AstraZeneca, Eli Lilly in focus as US panel weighs routine kidney disease screening

An influential panel of U.S. experts has added the screening for chronic kidney disease (CKD) to its list of preventive services under active consideration, Reuters reported on Monday, citing the group chair.

The identification of new patients could expand sales of new treatments targeted at the disease. AstraZeneca (NASDAQ:AZN) has FDA approval for SGLT2 inhibitor Farxiga to slow progression of early-stage kidney disease. Eli Lilly (LLY) and Boehringer Ingelheim are developing their diabetes medication Jardiance to target CKD.

The government-backed panel last addressed the issue in 2012, noting inadequate evidence to assess routine screening for CKD in the asymptomatic stage of the disease.

USPSTF recommendations typically lead to payor coverage for diagnostics. Kidney disease screening usually involves a blood test for a waste product known as creatinine and a urine test for the protein albumin.

» continue to Seeking Alpha